TY - JOUR
T1 - Longitudinal associations between adiponectin and cardiac structure differ by hypertensive status
T2 - Coronary Artery Risk Development in Young Adults
AU - Sharma, Shishir
AU - Colangelo, Laura A.
AU - Lloyd-Jones, Donald
AU - Jacobs, David R.
AU - Gross, Myron D.
AU - Gidding, Samuel S.
AU - Greenland, Philip
N1 - Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc.
PY - 2016
Y1 - 2016
N2 - Objective We studied the longitudinal association between adiponectin and cardiac structure and function 10 years later stratified by hypertension status. Methods This was a multicenter longitudinal study of black and white men and women that began in 1985-1986, when participants were 18-30 years old. Adiponectin was measured at year 15 (2000-2001). Echocardiograms were completed at year 25 (2010-2011). Participants were stratified by the presence of hypertension. Risk factoradjusted echocardiographic variables were compared across adiponectin quintiles. Linear and quadratic regression models were also derived for risk factoradjusted echocardiographic variables. Results Relative to the lowest quintile of adiponectin, participants from the highest quintile had a 6% lower left ventricular mass index (LVMi) among normotensives and an 8% higher LVMi among hypertensives. Among normotensive participants, regression analysis showed a linear inverse relationship between adiponectin and LV mass, LVMi, posterior wall thickness, and ventricular septal thickness (all P≤0.05). Among hypertensive participants, regression analysis showed a U-shaped relationship between adiponectin and LV mass, LVMi, posterior wall thickness, and ventricular septal thickness (P≤0.005 for all quadratic terms). Conclusion Among normotensive participants, higher adiponectin may be a useful marker of less adverse future cardiac structure. Further study is required to determine whether adiponectin receptor agonists may provide a benefit among these individuals. Among hypertensive participants, further study is required to assess the prognostic and therapeutic use of adiponectin.
AB - Objective We studied the longitudinal association between adiponectin and cardiac structure and function 10 years later stratified by hypertension status. Methods This was a multicenter longitudinal study of black and white men and women that began in 1985-1986, when participants were 18-30 years old. Adiponectin was measured at year 15 (2000-2001). Echocardiograms were completed at year 25 (2010-2011). Participants were stratified by the presence of hypertension. Risk factoradjusted echocardiographic variables were compared across adiponectin quintiles. Linear and quadratic regression models were also derived for risk factoradjusted echocardiographic variables. Results Relative to the lowest quintile of adiponectin, participants from the highest quintile had a 6% lower left ventricular mass index (LVMi) among normotensives and an 8% higher LVMi among hypertensives. Among normotensive participants, regression analysis showed a linear inverse relationship between adiponectin and LV mass, LVMi, posterior wall thickness, and ventricular septal thickness (all P≤0.05). Among hypertensive participants, regression analysis showed a U-shaped relationship between adiponectin and LV mass, LVMi, posterior wall thickness, and ventricular septal thickness (P≤0.005 for all quadratic terms). Conclusion Among normotensive participants, higher adiponectin may be a useful marker of less adverse future cardiac structure. Further study is required to determine whether adiponectin receptor agonists may provide a benefit among these individuals. Among hypertensive participants, further study is required to assess the prognostic and therapeutic use of adiponectin.
KW - adipokine
KW - adiponectin
KW - left ventricular mass
KW - remodeling
UR - http://www.scopus.com/inward/record.url?scp=85006219592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006219592&partnerID=8YFLogxK
U2 - 10.1097/XCE.0000000000000080
DO - 10.1097/XCE.0000000000000080
M3 - Article
C2 - 27525195
AN - SCOPUS:85006219592
SN - 2574-0954
VL - 5
SP - 57
EP - 63
JO - Cardiovascular Endocrinology
JF - Cardiovascular Endocrinology
IS - 2
ER -